<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Singh</title>
	<atom:link href="http://www.tapanray.in/tag/singh/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why Many Successful CEOs Don’t Want to Retire &#8211; in Pharma Too?</title>
		<link>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-many-successful-ceos-dont-want-to-retire-in-pharma-too</link>
		<comments>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/#comments</comments>
		<pubDate>Mon, 12 Nov 2018 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[70]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Aditya]]></category>
		<category><![CDATA[Aging]]></category>
		<category><![CDATA[alkem]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Basudeo]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Frazier]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[HDFC]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ITC]]></category>
		<category><![CDATA[Jack]]></category>
		<category><![CDATA[Kenneth]]></category>
		<category><![CDATA[L&T]]></category>
		<category><![CDATA[listed]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[MD]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Miles]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Naik]]></category>
		<category><![CDATA[Narain]]></category>
		<category><![CDATA[Pankaj]]></category>
		<category><![CDATA[Patel]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[publicly]]></category>
		<category><![CDATA[Puri]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RBI]]></category>
		<category><![CDATA[retire]]></category>
		<category><![CDATA[retirement]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Welsh]]></category>
		<category><![CDATA[white]]></category>
		<category><![CDATA[years]]></category>
		<category><![CDATA[Yogeshwar]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9256</guid>
		<description><![CDATA[“On Eve of Retirement, Jack Welch Decides to Stick Around GE a Bit,” reported the Wall Street Journal (WSJ) on October 23, 2000. Nevertheless, even the legendary Jack Welsh was made no exception to GE’s mandatory retirement policy for the &#8230; <a href="http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Patent Linkage’: Can The Core Issue Be Resolved?</title>
		<link>http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=patent-linkage-can-the-core-issue-be-resolved</link>
		<comments>http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/#comments</comments>
		<pubDate>Mon, 23 Feb 2015 00:00:45 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[administrative]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[Arun]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[Corporation]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Froman]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Jaitley]]></category>
		<category><![CDATA[Kher]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[linkage]]></category>
		<category><![CDATA[measures]]></category>
		<category><![CDATA[Mike]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[PMO]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pratibha]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[rajiv]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[RTI]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[status]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TPF]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[visit]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6392</guid>
		<description><![CDATA[On February 10, 2015, a leading business daily of India, quoted the Commerce Secretary of India &#8211; Rajeev Kher, saying, “India needs to relook at its Intellectual Property Rights (IPR) Policy with a view to bring in a differentiated regime &#8230; <a href="http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/patent-linkage-can-the-core-issue-be-resolved/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>With Free Medicines In, Would The New Government Revisit ‘Universal Health Coverage’ Soon?</title>
		<link>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon</link>
		<comments>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/#comments</comments>
		<pubDate>Mon, 02 Jun 2014 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[CMSS]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[consulting]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[distribution]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[harsh]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[insurance]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Manmohan]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Obamacare]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[oop]]></category>
		<category><![CDATA[OP]]></category>
		<category><![CDATA[out]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[pocket]]></category>
		<category><![CDATA[Rajasthan]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[Srinath]]></category>
		<category><![CDATA[Tamil Nadu]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[Universal]]></category>
		<category><![CDATA[Vardhan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5462</guid>
		<description><![CDATA[Friday last, the new Union Health Minister Dr. Harsh Vardhan reportedly announced that the his ministry would soon start work on distributing free medicines through public hospitals across the country. For this purpose the Minister would soon call a meeting of the &#8230; <a href="http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/with-free-medicines-in-would-the-new-government-revisit-universal-health-coverage-soon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Try To Reinvent The Wheel With So Much Of Hullabaloo?</title>
		<link>http://www.tapanray.in/why-try-to-reinvent-the-wheel-with-so-much-of-hullabaloo/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-try-to-reinvent-the-wheel-with-so-much-of-hullabaloo</link>
		<comments>http://www.tapanray.in/why-try-to-reinvent-the-wheel-with-so-much-of-hullabaloo/#comments</comments>
		<pubDate>Wed, 19 Mar 2014 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Ahluwalia]]></category>
		<category><![CDATA[authorized]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HLEG]]></category>
		<category><![CDATA[hullabaloo]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Montek]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHFI]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[reinvent]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[Srinath]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[UHC]]></category>
		<category><![CDATA[wheel]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5112</guid>
		<description><![CDATA[A recent IMS study, apparently ‘authorized’ (whatever it means) by the Planning Commission of India has reportedly suggested various ‘ways to make drugs affordable in India’. Though there does not appear to be anything new in the reported suggestions, the &#8230; <a href="http://www.tapanray.in/why-try-to-reinvent-the-wheel-with-so-much-of-hullabaloo/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-try-to-reinvent-the-wheel-with-so-much-of-hullabaloo/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
